Today: 29 April 2026
Browse Category

NSE:RELINFRA 22 December 2025

Reliance Infrastructure Trading Restricted Under IBC Stage 1 on Dec 22, 2025; Reliance Power Slides as Investors Seek Clarity

Reliance Infrastructure Trading Restricted Under IBC Stage 1 on Dec 22, 2025; Reliance Power Slides as Investors Seek Clarity

Reliance Infrastructure Ltd. was placed under restricted trading linked to the Insolvency and Bankruptcy Code on December 22, 2025, prompting confusion among retail investors and a sharp drop in Reliance Power Ltd. Trading was limited to a “once-a-week” sell-only window on some platforms, with holdings disappearing from certain broker terminals. Liquidity concerns and regulatory uncertainty drove volatility across Anil Ambani-group stocks.
22 December 2025
···

Stock Market Today

  • Ceres Power Surges Past Rolls-Royce, Nvidia, BP in FTSE 250 Rally
    April 29, 2026, 9:27 AM EDT. Ceres Power (LSE:CWR) leads the FTSE 250 stock gains in 2026 with a staggering 176% rise year-to-date, far outpacing Rolls-Royce, Nvidia and BP. The clean energy tech firm, specializing in licensing advanced solid oxide fuel cell and hydrogen technology, posted a remarkable 933% gain over the last year. Despite declining revenues - £32.6 million in 2025 down from £51.9 million the previous year - and no expected profits in 2026 or 2027, investor enthusiasm is fueled by the AI-driven data center boom. Its recent collaboration with Centrica aims to deploy efficient on-site power solutions swiftly for AI hubs and logistics centers. This positions Ceres as a crucial 'picks and shovels' provider amid the AI energy surge. However, over five years, the stock remains down 55%, prompting debate on its current valuation.

Latest article

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
Go toTop